Page last updated: 2024-10-24

positive regulation of cardiac muscle fiber development

Definition

Target type: biologicalprocess

Any process that activates, maintains or increases the frequency, rate or extent of cardiac muscle fiber development. [GOC:vk]

Positive regulation of cardiac muscle fiber development is a complex biological process that ensures the proper formation and function of the heart muscle. This process involves a coordinated interplay of various molecular mechanisms, including gene expression, signaling pathways, and cellular interactions.

**1. Gene Expression:**

* **Transcription factors:** Master regulators like MyoD, MEF2, and GATA4 play crucial roles in activating the expression of genes essential for cardiac muscle development. These factors bind to specific DNA sequences in the regulatory regions of cardiac muscle genes, promoting their transcription.
* **MicroRNAs:** Small non-coding RNAs like miR-1 and miR-133 fine-tune gene expression by targeting mRNAs for degradation or translational repression. These microRNAs have been implicated in regulating the expression of genes involved in cardiomyocyte growth, differentiation, and contractility.

**2. Signaling Pathways:**

* **Wnt signaling pathway:** This pathway plays a role in regulating cardiomyocyte proliferation and differentiation. Wnt ligands activate downstream signaling components, leading to the activation of transcription factors that promote cardiac muscle development.
* **Hedgehog signaling pathway:** This pathway contributes to the development of the heart tube and the formation of the ventricular chambers. Sonic hedgehog (Shh), a secreted protein, activates downstream signaling pathways that regulate cell proliferation, survival, and differentiation.
* **TGF-β signaling pathway:** This pathway is involved in regulating cardiomyocyte survival, growth, and maturation. TGF-β ligands bind to receptors on the cell surface, activating downstream signaling cascades that regulate gene expression and cell behavior.

**3. Cellular Interactions:**

* **Cell-cell interactions:** Adherens junctions and gap junctions between cardiomyocytes facilitate communication and coordination of their functions. These junctions are critical for the proper formation and function of the heart muscle.
* **Extracellular matrix (ECM):** The ECM provides structural support and regulates cell adhesion, migration, and differentiation. Components of the ECM, such as laminin and fibronectin, interact with receptors on cardiomyocytes, influencing their development and function.

**4. Post-translational Modifications:**

* **Phosphorylation:** Modifications like phosphorylation play a role in regulating the activity of proteins involved in cardiac muscle development. These modifications can alter protein stability, localization, and interactions, impacting their biological functions.
* **Ubiquitination:** This process targets proteins for degradation, contributing to the proper regulation of cardiac muscle development by eliminating proteins that are no longer needed.

**Overall, positive regulation of cardiac muscle fiber development is a multifaceted process involving the interplay of various molecular mechanisms. Dysregulation of these processes can lead to heart defects and diseases, highlighting the importance of understanding the complexities of cardiac muscle development.**'
"

Proteins (1)

ProteinDefinitionTaxonomy
Bone morphogenetic protein 4A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644]Homo sapiens (human)

Compounds (3)

CompoundDefinitionClassesRoles
dorsomorphindorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.

dorsomorphin: an AMPK inhibitor
aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines
bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ldn 193189LDN 193189: inhibits bone morphogenetic protein signalingpyrimidines
ml347ML347: an ALK2 inhibitor; structure in first source